deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04757363

A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

A Phase II Study of Nivolumab in Combination With FOLFOX and Regorafenib in Patients With HER2-Negative Metastatic Esophagogastric Cancer

Sponsor: Bayer

Conditions Esophagogastric Cancer HER2-Negative
Interventions FOLFOX chemotherapy with oxaliplatin nivolumab regorafenib
Updated 11 times since 2021 Last updated: Mar 2, 2026 Started: Feb 11, 2021 Primary completion: Feb 28, 2027 Completion: Feb 28, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04757363, this PHASE2 trial focuses on Esophagogastric Cancer and HER2-Negative and remains ongoing. Sponsored by Bayer, it has been updated 11 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshotRecruiting~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshotRecruiting~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshotRecruiting~Feb 2022 – ~Dec 2022 · 10 months · monthly snapshotRecruiting~Dec 2022 – ~Dec 2023 · 12 months · monthly snapshotActive Not Recruiting~Dec 2023 – ~Apr 2024 · 4 months · monthly snapshotActive Not Recruiting~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshotActive Not Recruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotActive Not Recruiting~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshotActive Not Recruiting~Apr 2025 – ~Mar 2026 · 11 months · monthly snapshotActive Not Recruiting~Mar 2026 – present · 4 months · monthly snapshotActive Not Recruiting

Change History

11 versions recorded

  1. Mar 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Apr 2025 — Mar 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 6 earlier versions

  1. Dec 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Dec 2022 — Dec 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Feb 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  4. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE2

  5. Sep 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  6. Mar 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

    First recorded

Feb 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
  • Bristol-Myers Squibb
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations